Loading…
Werewolf Therapeutics, Inc. is projected to decline to $0.487 by 2027, a -1% move from its current price of $0.49. HOWL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4659 | $0.49 | $0.5154 | +0.01% |
| May 30 | $0.4563 | $0.4901 | $0.5264 | +0.02% |
| May 31 | $0.4491 | $0.4901 | $0.535 | +0.03% |
| Jun 1 | $0.4431 | $0.4902 | $0.5423 | +0.04% |
| Jun 2 | $0.4379 | $0.4902 | $0.5489 | +0.05% |
| Jun 3 | $0.4332 | $0.4903 | $0.5549 | +0.05% |
| Jun 4 | $0.429 | $0.4903 | $0.5604 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.429 | $0.4903 | $0.5604 | +0.06% |
| Week 2 | $0.4061 | $0.4906 | $0.5927 | +0.13% |
| Week 3 | $0.3895 | $0.4909 | $0.6188 | +0.19% |
| Week 4 | $0.376 | $0.4913 | $0.6418 | +0.26% |
| Week 5 | $0.3646 | $0.4916 | $0.6628 | +0.32% |
| Week 6 | $0.3545 | $0.4919 | $0.6824 | +0.38% |
| Week 7 | $0.3456 | $0.4922 | $0.701 | +0.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Werewolf Therapeutics, Inc. is a healthcare company that develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune‑mediated conditions. It designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Werewolf Therapeutics, Inc. (HOWL) is a healthcare company focused on immunotherapy approaches for cancer and immune‑mediated conditions, with a portfolio that centers on conditionally activated INDUKINE molecules via its PREDATOR platform. The company operates in the healthcare sector and trades as HOWL in the public markets.
As of now, the stock carries a current price of $0.49 and a market capitalization of $23.81M, with a rank of 4847. The near‑term technical landscape shows bearish tendencies, while multi‑year forecasts point to a higher average price in the 2030s through 2050, albeit with notable volatility.
A major floor 83.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
The nearest ceiling, 98.0% above — a clean break opens room to run.
A major ceiling 139.9% above — clearing it would confirm fresh momentum.
Key HOWL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HOWL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4514 | Buy | $0.4693 | Buy |
| MA 10 | $0.4822 | Buy | $0.4979 | Sell |
| MA 20 | $0.5774 | Sell | $0.572 | Sell |
| MA 50 | $0.7582 | Sell | $0.6806 | Sell |
| MA 100 | $0.7074 | Sell | $0.7659 | Sell |
| MA 200 | $1.01 | Sell | $0.941 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.53 | Neutral |
| Stoch RSI (14) | 70.65 | Neutral |
| CCI (20) | -60.78 | Neutral |
| Williams %R (14) | -73.64 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -27.94 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 26.36 | Neutral |
| TRIX (15) | -1.75 | Sell |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 37.77 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.45 | Buy |
| ADX (14) | 31.66 | Sell |
| ATR (14) | 0.03 | Info |
Near‑term technical picture is bearish with a RSI of 40. The 30‑day range spans $0.3512 to $0.6836, and the current price sits around $0.49.
The stock trades below key moving averages, with a SMA50 of $0.7582 and a SMA200 of $1.01, suggesting negative momentum in the short run.
Support is at $0.422 and resistance at $0.97, defining a near‑term trading band. The stock exhibits high volatility, with annualized volatility at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.422 | $0.49 | $0.6067 | 0% | Neutral | |
| $0.3544 | $0.487 | $0.7233 | -1% | Neutral | |
| $0.3016 | $0.4381 | $0.6899 | -11% | Neutral | |
| $0.2424 | $0.3693 | $0.6087 | -25% | Bearish | |
| $0.3131 | $0.4981 | $0.8528 | +2% | Neutral | |
| $0.3736 | $0.619 | $1.09 | +26% | Bullish | |
| $0.3738 | $0.6438 | $1.17 | +31% | Bullish | |
| $0.3656 | $0.6534 | $1.22 | +33% | Bullish | |
| $0.3302 | $0.6118 | $1.17 | +25% | Bullish | |
| $0.3189 | $0.612 | $1.20 | +25% | Bullish | |
| $0.4132 | $0.9181 | $1.97 | +87% | Bullish | |
| $0.7281 | $1.62 | $3.72 | +230% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.422 | $0.49 | $0.579 | +0.00% |
| June 2026 | $0.411 | $0.4917 | $0.6089 | +0.36% |
| July 2026 | $0.4064 | $0.4941 | $0.6267 | +0.48% |
| August 2026 | $0.3745 | $0.461 | $0.5955 | -6.70% |
| September 2026 | $0.3554 | $0.4421 | $0.5796 | -4.10% |
| October 2026 | $0.3664 | $0.4602 | $0.6114 | +4.09% |
| November 2026 | $0.3657 | $0.4632 | $0.6226 | +0.66% |
| December 2026 | $0.3496 | $0.4465 | $0.6067 | -3.62% |
Click any year to see its month-by-month HOWL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HOWL price prediction for 2026 points to an average of $0.49 (low $0.422, high $0.6067) — a potential gain of 0% on today's $0.49. A consolidation phase looks the most probable path here.
In 2027, HOWL is projected to trade between $0.3544 and $0.7233, averaging $0.487 — a potential decline of -1% from today's $0.49. That is -1% versus the projected 2026 average. Price action looks broadly range-bound.
Werewolf Therapeutics, Inc.'s 2028 outlook centres on $0.4381, within a $0.3016 to $0.6899 range. That is -10% versus the projected 2027 average. That marks a -11% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, HOWL could reach as high as $0.6087, with a base case around $0.3693 and support toward $0.2424 — roughly -25% from $0.49. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect HOWL to range from $0.3131 to $0.8528 through 2030. The $0.4981 average target implies a +2% move from current prices. That is up +35% on the projected 2029 average. A consolidation phase looks the most probable path here.
The HOWL price prediction for 2031 points to an average of $0.619 (low $0.3736, high $1.09) — a potential gain of +26% on today's $0.49. Momentum favours further upside here.
In 2032, HOWL is projected to trade between $0.3738 and $1.17, averaging $0.6438 — a potential gain of +31% from today's $0.49. That is up +4% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Werewolf Therapeutics, Inc.'s 2033 outlook centres on $0.6534, within a $0.3656 to $1.22 range. That is up +1% on the projected 2032 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2034, HOWL could reach as high as $1.17, with a base case around $0.6118 and support toward $0.3302 — roughly +25% from $0.49. Buyers look set to stay in control over this stretch.
Expect HOWL to range from $0.3189 to $1.20 through 2035. The $0.612 average target implies a +25% move from current prices. That is up 0% on the projected 2034 average. Momentum favours further upside here.
The HOWL price prediction for 2040 points to an average of $0.9181 (low $0.4132, high $1.97) — a potential gain of +87% on today's $0.49. Buyers look set to stay in control over this stretch.
In 2050, HOWL is projected to trade between $0.7281 and $3.72, averaging $1.62 — a potential gain of +230% from today's $0.49. That is up +76% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HOWL today (≈ 2,040.816327 HOWL) could be worth
$3,301.89
+$2,301.89 (+230%) by 2050 · US Dollar
Based on the average projected HOWL price of $1.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HOWLwould be worth at today's price.
$1,000 invested in HOWL on May 27, 2025 (≈ 840.336094 HOWL) would be worth
$411.76
-$588.24 (-58.8%) today · 0.41× · US Dollar
Based on a HOWL entry price of $1.19 vs. today's $0.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.438 | $1,118.72 | +11.9% |
| 1 month ago | $0.83 | $590.36 | -41.0% |
| 3 months ago | $0.632 | $775.32 | -22.5% |
| 6 months ago | $1 | $490 | -51.0% |
| 1 year ago | $1.19 | $411.76 | -58.8% |
| All time (5.0y) ago | $13.81 | $35.48 | -96.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HOWL forecast.
Our base-case forecast reaches $0.98 around 2050.
Implied market cap at $0.98: $47.62M
The multi‑year forecast shows a path from a 2026 baseline around $0.49 toward higher levels later in the horizon. In 2026 the average price is forecast at $0.49 with a max of $0.6067 and a neutral sentiment; the 2030 forecast places the average at $0.4981 with a 1.7% ROI.
From 2031 onward, the outlook turns increasingly bullish, with 2031 at an average of $0.619 and a 26.3% ROI, 2032 at $0.6438 with 31.4% ROI, and 2033 at $0.6534 with 33.4% ROI. By 2040 the average is $0.9181 and the ROI is 87.4%, culminating in 2050 with an average of $1.62 and a 230.2% ROI (max $3.72).
Overall, the forecast suggests meaningful upside in the long run, but it also reflects substantial volatility and uncertainty in the nearer term. These estimates are not guarantees and should be considered within the context of the asset’s risk profile.
Tap a question to reveal the answer.
2030 forecast shows an average price of $0.4981 with a maximum of $0.8528 and a 1.7% ROI; sentiment is neutral.
Near term includes bearish signals with 2029 showing a -24.6% ROI, while the mid to long term turns bullish from 2031 onward, with positive ROIs and higher expected averages by 2040 and 2050; these are estimates, not guarantees.
Yes, the long‑term forecast shows a 2050 average of $1.62 and a max of $3.72, indicating upside beyond $1 by the 2040–2050 horizon.
The 30‑day range is $0.3512 to $0.6836, current price is $0.49, RSI is 40 (bearish sentiment). The stock is trading below the SMA50 ($0.7582) and SMA200 ($1.01).
Current price is $0.49 and market cap is $23.81M, with a rank of 4847.
Werewolf Therapeutics, Inc. Community Discussion
0Share your Werewolf Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.